Moe A, Liow E, Redfern A, Swarbrick N, et al. A phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (SUBDUE-1, SUB-urothelial BJU Int 2021 May 6. doi: 10.1111/bju.15365.
PMID: 33960102